

We greatly appreciate all your hard work.

Martin

---

**From:** Johnson, Martin S. (NIH/NIAID) [E]

**Sent:** Friday, March 13, 2020 6:45 PM

**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6); Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [E] <(b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6); Crum, Wayne (NIH/NIAID) [E] (b) (6); Erbeling, Emily (NIH/NIAID) [E] (b) (6)>

**Cc:** Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Doepel, Laurie (NIH/NIAID) [E] (b) (6); Gilles, Sharon (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Law, Kim (NIH/NIAID) [E] (b) (6); Lee, Kun-Lin (NIH/NIAID) [E] (b) (6); Bushar, Nicholas (NIH/NIAID) [E] (b) (6); Schneider, Johanna (NIH/NIAID) [E] (b) (6)>

**Subject:** RE: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 3/12/20

Tony,

Since we our last report we have increased spending on the COVID-19 response by \$1.5M for a total YTD spending of \$14.1M.

The \$1.5M increase is for the following:

\$1.0M awarded to set-up clinical sites at Emory and U. Washington Seattle for adaptable RCT of remdesivir.